HONG-HANH NGUYEN: Open Payments
NPI 1760021752 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,198 in 73 payments from 7 companies in 2025. Trend: 2023 $358 · 2024 $1,132 · 2025 $3,198
Food & beverage: $2,698Speaker / faculty: $500
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 28 | $1,307 |
| Gilead Sciences, Inc. | 17 | $763 |
| Ipsen Biopharmaceuticals, Inc | 4 | $565 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 19 | $407 |
| ABBVIE INC. | 2 | $69 |
| ORPHALAN INC | 2 | $62 |
| Novo Nordisk Inc | 1 | $24 |
Products named: REZDIFFRA, IQIRVO, XIFAXAN, CUVRIOR, MAVYRET, Wegovy, CREON.
Industry payments across TX — which companies pay providers there.
